MOMM Diagnostics
MOMM Diagnostics GmbH is a Basel-based Swiss medtech startup developing the eFlow point-of-care diagnostic platform and the préXclude rapid preeclampsia test, which uses sFlt-1 and PlGF biomarkers to deliver lab-quality results in minutes from a fingerstick blood sample for healthcare providers, pregnant women, and researchers.
- Company typePrivate
- Founded2018
- HeadquartersBasel, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What MOMM Diagnostics does
MOMM Diagnostics GmbH is a Basel-based Swiss medtech startup founded in 2018 that is developing a rapid in-vitro diagnostic test for the early detection of preeclampsia. The company's platform-plus-assay architecture consists of the eFlow, a patented compact electrochemical biosensor reader designed for near-patient settings, and the préXclude, a cartridge-based rapid test that quantifies the established preeclampsia biomarkers sFlt-1 and PlGF. The company claims over 95% accuracy in centralized lab assays and aims to deliver results in minutes from a simple fingerstick blood sample, targeting a gap left by current lab-based diagnostics that take days to return results for a condition affecting 5-8% of all pregnancies.
The company was co-founded through a partnership between US-based Avails Medical, Inc. and Swiss federal research institute Empa, and has since built additional research collaborations with FHNW School of Life Sciences, CSEM, and the University of Basel NanoScience. Its management team is led by PhD co-founder and CEO Mathias Wipf and PhD Director of R&D Christopher Wood, supported by PhD-level scientific, medical, and business advisors. The intended go-to-market is direct enterprise sales to healthcare providers — hospitals and prenatal care clinics — with secondary use cases in at-home testing for pregnant women and research applications for novel biomarker development.
The company is pre-revenue and pre-commercial: both eFlow and préXclude remain in the development phase and are not yet available for commercial use. The intended revenue model combines one-time hardware sales of the eFlow reader with recurring cartridge consumables for préXclude tests, supplemented by future professional services for biomarker testing. To date, funding has come almost entirely from non-dilutive sources, including Innosuisse grants, 5HT Digital Hub Chemistry Health, CE Switzerland, and the University of Basel, plus a 2018 Venture Kick seed and a $500,000 grant from the Bill & Melinda Gates Foundation awarded in October 2025. No venture capital or private equity rounds are disclosed.
MOMM Diagnostics firmographics
Firmographics- Name
- MOMM Diagnostics
- Legal name
- MOMM Diagnostics GmbH
- Website
- https://mommdiagnostics.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- MOMM Diagnostics GmbH is a Basel-based Swiss medtech startup developing the eFlow point-of-care diagnostic platform and the préXclude rapid preeclampsia test, which uses sFlt-1 and PlGF biomarkers to deliver lab-quality results in minutes from a fingerstick blood sample for healthcare providers, pregnant women, and researchers.
- Ownership category
- akta.pro rank
MOMM Diagnostics industry classification
Industry- Product category
- In-vitro diagnostics for preeclampsia
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection) (HLAHAOAF)
- akta.pro secondary industry
- Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)
Keywords
Where MOMM Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Basel
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
MOMM Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- préXclude Test Kits: Revenue anticipated from sale of rapid preeclampsia test cartridges for the eFlow platform. Products are currently in development phase and not yet commercially available.
- eFlow Platform Hardware: Compact diagnostic reader device sales to healthcare providers for near-patient testing. Currently in development phase.
- Biomarker Testing Services: Future opportunity to offer novel biomarker testing on MOMM's eFlow platform to researchers and diagnostic providers.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels3 records
MOMM Diagnostics product offering
Product offeringCore offering
MOMM Diagnostics develops an in-vitro diagnostic solution for the early detection of preeclampsia. Its offering centers on the préXclude rapid test cartridge — measuring the established biomarkers sFlt-1 and PlGF with reported accuracy above 95% in centralized lab assays — which runs on the company's patented eFlow compact reader platform. The combined product enables near-patient, fingerstick-based testing that returns results in minutes, intended for hospitals, clinics and at-home prenatal monitoring.
Product overview
MOMM Diagnostics offers a platform-plus-assay architecture consisting of the eFlow diagnostics platform and the préXclude rapid preeclampsia test. The eFlow is a compact, patented reader device designed for near-patient settings that delivers lab-quality sensitivity at point-of-care. The préXclude assay is a cartridge-based rapid diagnostic test that runs on the eFlow platform, utilizing established biomarkers (sFlt-1 and PlGF) to detect preeclampsia risk with over 95% accuracy, requiring only a fingerstick blood sample and delivering results in minutes. Both products are currently in the development phase.
Differentiator
Problem solved
Functional benefit
Brands
- préXclude: Ground-breaking rapid preeclampsia test designed for the eFlow system - the fastest and most precise method for detecting preeclampsia in pregnant women. Utilizes biomarkers sFlt-1 and PlGF with over 95% accuracy.
- eFlow
Products and services
- préXclude Rapid preeclampsia diagnostic test cartridge that runs on the eFlow reader. Measures the biomarkers sFlt-1 and PlGF from a simple fingerstick blood sample with reported accuracy above 95% in centralized lab assays and delivers results in minutes. Intended for near-patient use in hospitals, clinics and at-home prenatal monitoring.
- eFlow Patented compact diagnostic reader platform designed for near-patient settings including clinics and at-home testing. Combines electrochemical biosensor technology with a compact, low-cost reader to deliver lab-based assay sensitivity at point-of-care with rapid results and minimal hands-on time and training required.
Quantifiable outcome
- Over 95% accuracy rate in centralized lab assays
- +2 more outcomes
Companies that use MOMM Diagnostics
Customer profileSegments3 records
Ideal customer profiles2 records
MOMM Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
MOMM Diagnostics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and supporting.
- Avails Medical, Inc.coreCo-founding partner of MOMM Diagnostics startup. Contributed to the establishment and technology foundation of the company alongside Empa research institute. This strategic partnership provided the foundational expertise for developing the eFlow diagnostics platform.
- Empa (Swiss Federal Laboratories for Materials Science and Technology)coreSwiss research institute that partnered with Avails Medical to co-found MOMM Diagnostics. Empa contributed research expertise enabling the development of groundbreaking eFlow technology and préXclude rapid preeclampsia test.
- FHNW School of Life SciencessupportingResearch collaboration providing access to unique ecosystem for innovation. FHNW School of Life Sciences contributes expertise supporting MOMM's test menu expansion and technology development.
- CSEM (Swiss Center for Electronics and Microtechnology)supportingSwiss research institution collaboration providing unique ecosystem for innovation. CSEM contributes technical expertise and infrastructure for MOMM Diagnostics technology development.
Scale indicators3 records
Recent moves6 records
Expansion highlights4 records
MOMM Diagnostics competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
MOMM Diagnostics social profiles
Digital presenceMOMM Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
MOMM Diagnostics leadership team
Management profileNumber of profiles
Profiles5 records
MOMM Diagnostics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MOMM Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MOMM Diagnostics
What does MOMM Diagnostics do?
MOMM Diagnostics develops an in-vitro diagnostic solution for the early detection of preeclampsia. Its offering centers on the préXclude rapid test cartridge — measuring the established biomarkers sFlt-1 and PlGF with reported accuracy above 95% in centralized lab assays — which runs on the company's patented eFlow compact reader platform. The combined product enables near-patient, fingerstick-based testing that returns results in minutes, intended for hospitals, clinics and at-home prenatal monitoring.
Is MOMM Diagnostics a public or private company?
MOMM Diagnostics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was MOMM Diagnostics founded?
MOMM Diagnostics was founded in 2018. It employs 1 to 10 people.
Where is MOMM Diagnostics based?
MOMM Diagnostics is headquartered in Basel, Switzerland, in the Europe region.
How does MOMM Diagnostics make money?
Three revenue lines are on record. préXclude Test Kits are the primary driver. The others are eFlow Platform Hardware and biomarker Testing Services.
Does MOMM Diagnostics have an API?
No public API is recorded for MOMM Diagnostics.
What industry is MOMM Diagnostics in?
MOMM Diagnostics's product category is In-vitro diagnostics for preeclampsia. Its primary akta.pro industry code is HLAHAOAF, Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection), with a secondary code of HLAHAAAI, Genetic, Cytogenetic & Prenatal Screening IVD. Its NAICS code is 325413 and its SIC code is 2835.